ARV 806
Alternative Names: ARV-806; ARV-806 KRAS protein degraders - Arvinas; PROTAC KRAS G12D degrader; PROTAC®YLatest Information Update: 03 Nov 2025
At a glance
- Originator Arvinas
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein degraders; Proteolysis
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 24 Oct 2025 Pharmacodynamics data from a preclinical trial in cancer released by Arvinas
- 22 Oct 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 29 May 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT07023731)